AI Article Synopsis
- Two cases are presented where intramuscular clozapine was used successfully in patients who were physically unwell and unable or unwilling to take oral medication.
- The treatment aimed to manage their psychotic symptoms, facilitating necessary medical care for their physical illnesses.
- Both patients showed significant improvement in mental health without any adverse effects, highlighting the safety and effectiveness of intramuscular clozapine in acute medical settings.
Article Abstract
We present two cases demonstrating safe and effective use of intramuscular clozapine for patients who are physically unwell in acute medical care settings. Both patients described were admitted to inpatient medical care units and required treatment with clozapine to control their psychotic symptoms, but were unable or unwilling to take oral clozapine. We describe the use of intramuscular clozapine in these patients, including dosing decisions, administration routes and frequency of dosing. Outcome was measured by a reduction in psychotic symptoms, sufficient to allow treatment for physical illness. Both patients successfully received intramuscular clozapine, allowing timely treatment of their physical health conditions. There were no adverse events, and significant improvement in their mental health presentations was achieved. We have shown that intramuscular clozapine is a safe and effective treatment for patients with serious mental health illness in the acute medical hospital.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141995 | PMC |
| http://dx.doi.org/10.1177/2050313X211004796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia.
BMJ Case Rep
August 2024
Kent and Medway NHS and Social Care Partnership Trust, Maidstone, UK
Clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. We present a patient with a diagnosis of schizoaffective disorder who was stable on clozapine for a decade until discontinuation due to thrombocytopenia. She experienced a relapse of her illness, presenting with psychotic and catatonic features with poor oral intake and physical health complications requiring a lengthy admission to the hospital.
View Article and Find Full Text PDFThe Challenge of Managing Refractory Psychosis Amid Multiple Medication Side Effects: A Case Report and Review of the Literature.
Cureus
December 2023
Psychiatry, Memorial Regional Hospital, Hollywood, USA.
Antipsychotics are the mainstay for the treatment of schizophrenia and other psychotic disorders; however, these agents are associated with an extensive side effect profile that may complicate treatment outcomes. We present the case of a 35-year-old woman with a history of schizoaffective disorder and five prior psychiatric hospitalizations. The patient first presented to the hospital for disorganized behavior, in addition to poor sleep, auditory hallucinations, and racing thoughts in the context of medication nonadherence.
View Article and Find Full Text PDFDevelopment of Lyophilised Eudragit Retard Nanoparticles for the Sustained Release of Clozapine via Intranasal Administration.
Pharmaceutics
May 2023
Laboratory of Drug Delivery Technology, Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Clozapine (CZP) is the only effective drug in schizophrenia resistant to typical antipsychotics. However, existing dosage forms (oral or orodispersible tablets, suspensions or intramuscular injection) show challenging limitations. After oral administration, CZP has low bioavailability due to a large first-pass effect, while the i.
View Article and Find Full Text PDFThird-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?
Front Psychiatry
November 2022
Department of Psychiatry, Dr. Carol Davila University Emergency Central Military Hospital, Bucharest, Romania.
Clozapine is considered « the golden standard » for the management of treatment-resistant schizophrenia, but many patients do not present adequate responsivity even to this antipsychotic. If we add the need to strictly monitor the hematologic and cardiometabolic adverse events during each clozapine trial and the difficulty of preserving therapeutic adherence in patients with low insight, residual negative/positive symptoms, or economic challenges, then the necessity of exploring alternative interventions for these patients becomes obvious. Also, in case of intolerance to clozapine or where clozapine did not induce remission, clinicians have to find new ways to help their patients.
View Article and Find Full Text PDFPaliperidone-Associated Sialorrhea: A Case Report With Review of Current Literature.
J Clin Psychopharmacol
September 2022
Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Medical Center, Heersink School of Medicine, Birmingham, AL.
Purpose/background: Antipsychotic-associated sialorrhea is a problematic adverse effect with potentially negative consequences on quality of life and medication adherence. While clozapine is the antipsychotic that is most associated with sialorrhea, there have been published reports of other second-generation antipsychotics associated with sialorrhea, including aripiprazole, olanzapine, quetiapine, and risperidone. Although drooling is mentioned within the package insert for paliperidone, to date there have been minimal published reports in which paliperidone is implicated as the offending agent.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!